A practical reference on CAS Registry Number: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-24 and is reviewed periodically as new material appears.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
According to the Centers for Disease Control and Prevention (CDC), average U.S. life expectancy at birth reached 79.0 years in 2024, its highest recorded level and an increase of 0.6 years over 2023. The CDC attributed the improvement mainly to lower mortality from unintentional injuries, COVID-19, heart disease, cancer, and homicide. Heart disease, cancer, and unintentional injuries remained the leading causes of death. In 2024, life expectancy at birth for American men rose to 76.5 years (+0.7 years compared to 2023), while life expectancy for women was 81.4 years (+0.3 years). Starting in 1998, life expectancy in the U.S. fell behind that of other wealthy industrialized countries, and Americans' "health disadvantage" gap has been increasing ever since. The Commonwealth Fund reported in 2020 that the U.S. had the highest suicide rate among the 11 high-income countries included in its study. Obesity affected 40.3% of U.S. adults aged 20 and older in August 2021–August 2023. The U.S. healthcare system far outspends that of any other country, measured both in per capita spending and as a percentage of GDP, but attains worse healthcare outcomes when compared to peer countries for reasons that are debated. The United States is the only developed country without a system of universal healthcare, and a significant proportion of the population that does not carry health insurance. Government-funded healthcare coverage for the poor (Medicaid) and for those age 65 and older (Medicare) is available to Americans who meet the programs' income or age qualifications.
The history of wound care spans from prehistory to modern medicine. Wounds naturally heal by themselves, but hunter-gatherers would have noticed several factors and certain herbal remedies would speed up or assist the process, especially if it was grievous. In ancient history, this was followed by the realisation of the necessity of hygiene and the halting of bleeding, where wound dressing techniques and surgery developed. Eventually the germ theory of disease also assisted in improving wound care.
The French Second Republic (French: Deuxième république française or La IIe République), officially the French Republic (République française), was the second republican formation of the government of France. The republic existed from 1848, when the monarchy fell, until its dissolution only four years later in 1852 upon the proclamation of the Second French Empire. Following the final defeat of Napoleon Bonaparte at the Battle of Waterloo, in June 1815, France had been reconstituted into a monarchy known as the Bourbon Restoration. After a brief period of revolutionary turmoil in 1830, royal power was again secured in the "July Monarchy", governed under principles of moderate conservatism and improved relations with the United Kingdom. In 1848, Europe erupted into a mass revolutionary wave in which many citizens challenged their royal leaders. Much of it was led by France in the February Revolution, overthrowing King Louis-Philippe. Radical and liberal factions of the population convened the French Second Republic in 1848. Attempting to restore the First French Republic's values on human rights and constitutional government, they adopted the motto of the First Republic; Liberté, Égalité, Fraternité. The republic was plagued with tribalist tendencies of its leading factions: royalists, proto-socialists, liberals, and conservatives. In this environment, Napoleon's nephew, Louis-Napoléon Bonaparte, established himself as a popular anti-establishment figure and was elected president in 1848.
Sources: en.wikipedia.org
== Military == The Armed Forces of Serbia and Montenegro (Serbian: Војска Србије и Црне Горе/Vojska Srbije i Crne Gore, ВСЦГ/VSCG), previously known as Army of Yugoslavia (Serbian: Војска Југославије/Vojska Jugoslavije, ВЈ/VJ) included ground forces with internal and border troops, naval forces, air and air defense forces, and civil defense. It was established from the remnants of the Yugoslav People's Army (JNA), the military of the SFR Yugoslavia. Several Bosnian Serb units of the VJ were transferred over to the Republika Srpska, during the course of the Bosnian War, leaving only units directly from Serbia and Montenegro in the armed forces. The VJ saw military action during the Yugoslav Wars, including the Siege of Dubrovnik, as well as the Kosovo War, and played combat roles during ethnic insurgencies. Following the Kosovo War, the VJ was forced to evacuate Kosovo, and in 2003 it was renamed the ''Armed Forces of Serbia and Montenegro.'' Following the dissolution of the Union between Serbia and Montenegro, units from each army were assigned to the independent republics of Serbia and Montenegro, as recruitment in the army was on a local, rather than Federal, level. Montenegro inherited the small navy of the FR Yugoslavia, due to Serbia being landlocked.
Silence was their way of maintaining control in these situations, but it often came at the expense of their health and the advancement of female health and medicine. This silence and control were most obviously seen when the health problem was related to the core of Ming fuke, or the sexual body. It was often in these diagnostic settings that women would choose silence. In addition, there would be a conflict between patient and doctor on the probability of her diagnosis. For example, a woman who thought herself to be past the point of child-bearing age, might not believe a doctor who diagnoses her as pregnant. This only resulted in more conflict.
The majority of human neoantigens identified in unbiased screens display a high predicted MHC binding affinity. Minor histocompatibility antigens, a conceptually similar antigen class are also correctly identified by MHC binding algorithms. Another potential filter examines whether the mutation is expected to improve MHC binding. The nature of the central T-cell receptor-exposed residues of MHC-bound peptides is associated with peptide immunogenicity.
== Pharmacokinetics == The oral bioavailability of brincidofovir is 13.4% as a tablet and 16.8% in a suspension. The metabolism of the drug is as such: once the drug enters the target infected cell, brincidofovir's phosphodiester bond is then hydrolyzed to generate cidofovir which is then phosphorylated to the active cidofovir diphosphate. The volume of distribution of the drug is 1230 L.
Sources: en.wikipedia.org
hypomorph A mutant allele that permits a subnormal expression of the gene's normal phenotype, e.g. by encoding an unstable enzyme which degrades too quickly to fully serve its function but which nevertheless is functional in some limited capacity, being generated in quantities sufficient for its reaction to proceed slowly or at low levels.
=== Lipids === The lipids found in green coffee include: linoleic acid, palmitic acid, oleic acid, stearic acid, arachidic acid, diterpenes, triglycerides, unsaturated long-chain fatty acids, esters, and amides. The total content of lipids in dried green coffee is 11.7–14 g/100 g. Lipids are present on the surface and in the interior matrix of green coffee beans. On the surface, they include derivatives of carboxylic acid-5-hydroxytryptamides with an amide bond to fatty acids (unsaturated C6 to C24) making up to 3% of total lipid content or 1200 to 1400 microgram/g dried green coffee bean. Such compounds form a wax-like cover on the surface of the coffee bean (200–300 mg lipids/100 g dried green coffee bean) protecting the interior matrix against oxidation and insects. Further, such molecules have antioxidative activity due to their chemical structure. Lipids of the interior tissue are triglycerides, linoleic acid (46% of total free lipids), palmitic acid (30% to 35% of total free lipids), and esters. Arabica beans have a higher content of lipids (13.5–17.4 g lipids/100 g dried green coffee beans) than robustas (9.8–10.7 g lipids/100 g dried green coffee beans). The content of diterpenes is about 20% of the lipid fraction. The diterpenes found in green coffee include cafestol, kahweol and 16-O-methylcafestol. Some of these diterpenes have been shown in in vitro experiments to protect liver tissue against chemical oxidation. In coffee oil from green coffee beans the diterpenes are esterified with saturated long chain fatty acids.
== Background/History == Izon Science Limited is a company incorporated as Australo Ltd. on January 10, 2005, by four New Zealand-based scientists. In 2007, Hans van der Voorn became CEO, and on November 17, 2008, the company was renamed Izon Science Limited. Initially focused on developing tunable resistive pulse sensing instruments for nanoparticle characterization, the company later expanded into developing tools for isolating exosomes and other extracellular vesicles from biological fluids. Presently, Izon Science develops and manufactures tools for nanoparticle characterization and separation, catering to academic researchers and diagnostics companies working with extracellular vesicles, as well as those involved in nanomedicine, viruses, and virus-like particles. The Exoid is one of Izon's latest tunable resistive pulse sensing instruments, succeeding the qViro-X, qMicro, and qNano. In June 2021, Izon Science relocated its headquarters from Burnside (Christchurch) to a larger facility on Show Place, Addington (Christchurch). The company currently employs approximately 70 individuals. Izon has received investment funds from Bolton Equities, a privately funded investor group based in New Zealand. Research partnerships include the University Medical Center Utrecht and the VU University Medical Center in the Netherlands, the Mayo Clinic, the National Institutes of Health, and Massachusetts General Hospital.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.